BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99:535-542. [PMID: 24401715 DOI: 10.3945/ajcn.113.068890] [Cited by in Crossref: 189] [Cited by in F6Publishing: 158] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Mizock BA. Probiotics. Disease-a-Month 2015;61:259-90. [DOI: 10.1016/j.disamonth.2015.03.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
2 Noureddin M, Zhang A, Loomba R. Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opin Emerg Drugs 2016;21:343-57. [PMID: 27501374 DOI: 10.1080/14728214.2016.1220533] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
3 Kazemi A, Soltani S, Ghorabi S, Keshtkar A, Daneshzad E, Nasri F, Mazloomi SM. Effect of probiotic and synbiotic supplementation on inflammatory markers in health and disease status: A systematic review and meta-analysis of clinical trials.Clin Nutr. 2020;39:789-819. [PMID: 31060892 DOI: 10.1016/j.clnu.2019.04.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
4 Bahrami A, Teymoori F, Eslamparast T, Sohrab G, Hejazi E, Poustchi H, Hekmatdoost A. Legume intake and risk of nonalcoholic fatty liver disease. Indian J Gastroenterol 2019;38:55-60. [DOI: 10.1007/s12664-019-00937-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zamani B, Farshbaf S, Golkar HR, Bahmani F, Asemi Z. Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial. Br J Nutr 2017;117:1095-102. [DOI: 10.1017/s000711451700085x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 6.8] [Reference Citation Analysis]
6 Rajani C, Jia W. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders. Clin Sci (Lond) 2018;132:791-811. [PMID: 29661926 DOI: 10.1042/CS20171328] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
7 Xie C, Halegoua-DeMarzio D. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? Nutrients. 2019;11. [PMID: 31752378 DOI: 10.3390/nu11112837] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
8 Hadi A, Alizadeh K, Hajianfar H, Mohammadi H, Miraghajani M. Efficacy of synbiotic supplementation in obesity treatment: A systematic review and meta-analysis of clinical trials. Crit Rev Food Sci Nutr 2020;60:584-96. [PMID: 30595036 DOI: 10.1080/10408398.2018.1545218] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
9 Sayari S, Neishaboori H, Jameshorani M. Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. Clin Mol Hepatol 2018;24:331-8. [PMID: 29890569 DOI: 10.3350/cmh.2018.0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
10 Ansari A, Bose S, Patra JK, Shin NR, Lim DW, Kim KW, Wang JH, Kim YM, Chin YW, Kim H. A Controlled Fermented Samjunghwan Herbal Formula Ameliorates Non-alcoholic Hepatosteatosis in HepG2 Cells and OLETF Rats. Front Pharmacol 2018;9:596. [PMID: 29971000 DOI: 10.3389/fphar.2018.00596] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
11 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
12 Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16:e34897. [PMID: 27110262 DOI: 10.5812/hepatmon.34897] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
13 Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract 2019;2019:1484598. [PMID: 31885541 DOI: 10.1155/2019/1484598] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
14 Bischoff SC, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Plauth M. ESPEN practical guideline: Clinical nutrition in liver disease. Clin Nutr 2020;39:3533-62. [PMID: 33213977 DOI: 10.1016/j.clnu.2020.09.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
15 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 58] [Article Influence: 17.5] [Reference Citation Analysis]
16 Machado MV, Cortez-Pinto H. Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. Int J Mol Sci. 2016;17:481. [PMID: 27043550 DOI: 10.3390/ijms17040481] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
17 Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol 2017;9:503-9. [PMID: 28443155 DOI: 10.4254/wjh.v9.i10.503] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
18 Mejía SÁ, Gutman LAB, Camarillo CO, Navarro RM, Becerra MCS, Santana LD, Cruz M, Pérez EH, Flores MD. Nicotinamide prevents sweet beverage-induced hepatic steatosis in rats by regulating the G6PD, NADPH/NADP+ and GSH/GSSG ratios and reducing oxidative and inflammatory stress. Eur J Pharmacol 2018;818:499-507. [PMID: 29069580 DOI: 10.1016/j.ejphar.2017.10.048] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
19 Bakhshimoghaddam F, Shateri K, Sina M, Hashemian M, Alizadeh M. Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. J Nutr 2018;148:1276-84. [PMID: 29931231 DOI: 10.1093/jn/nxy088] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 20.0] [Reference Citation Analysis]
20 Hannah WN, Harrison SA. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1365-1374. [PMID: 27052013 DOI: 10.1007/s10620-016-4153-y] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 12.6] [Reference Citation Analysis]
21 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Moyses HE, Clough GF, Wright M, Patel J, Bindels L, Delzenne NM, Calder PC, Byrne CD. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. Contemp Clin Trials 2018;71:113-23. [PMID: 29787859 DOI: 10.1016/j.cct.2018.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
22 Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, Yari Z, Hekmatdoost A. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019;33:2118-25. [PMID: 31264313 DOI: 10.1002/ptr.6406] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
23 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
24 Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, Clément K. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? Gastroenterology 2020;158:1881-98. [PMID: 32044317 DOI: 10.1053/j.gastro.2020.01.049] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 25.0] [Reference Citation Analysis]
25 Yuan T, Wang J, Chen L, Shan J, Di L. Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus. Journal of Functional Foods 2019;52:219-27. [DOI: 10.1016/j.jff.2018.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
26 Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. Br J Nutr. 2017;117:662-668. [PMID: 28345499 DOI: 10.1017/s0007114517000204] [Cited by in Crossref: 87] [Cited by in F6Publishing: 39] [Article Influence: 21.8] [Reference Citation Analysis]
27 Behrouz V, Jazayeri S, Aryaeian N, Zahedi MJ, Hosseini F. Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Middle East J Dig Dis 2017;9:150-7. [PMID: 28894517 DOI: 10.15171/mejdd.2017.66] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
28 Sharma N, Sircar A, Anders HJ, Gaikwad AB. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Arch Physiol Biochem 2020;:1-15. [PMID: 32223569 DOI: 10.1080/13813455.2020.1745851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Liu L, Li P, Liu Y, Zhang Y. Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Dig Dis Sci. 2019;64:3402-3412. [PMID: 31203554 DOI: 10.1007/s10620-019-05699-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
30 Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 2019;76:1541-58. [PMID: 30683985 DOI: 10.1007/s00018-019-03011-w] [Cited by in Crossref: 101] [Cited by in F6Publishing: 78] [Article Influence: 50.5] [Reference Citation Analysis]
31 Mansour-ghanaei F, Joukar F, Mobaraki SN, Mavaddati S, Hassanipour S, Sepehrimanesh M. Prevalence of non-alcoholic fatty liver disease in patients with diabetes mellitus, hyperlipidemia, obesity and polycystic ovary syndrome: A cross-sectional study in north of Iran. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:1591-6. [DOI: 10.1016/j.dsx.2019.03.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
32 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
33 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 96] [Reference Citation Analysis]
34 Hekmatdoost A, Shamsipour A, Meibodi M, Gheibizadeh N, Eslamparast T, Poustchi H. Adherence to the Dietary Approaches to Stop Hypertension (DASH) and risk of Nonalcoholic Fatty Liver Disease. Int J Food Sci Nutr. 2016;67:1024-1029. [PMID: 27436528 DOI: 10.1080/09637486.2016.1210101] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 8.4] [Reference Citation Analysis]
35 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
36 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 69] [Article Influence: 20.0] [Reference Citation Analysis]
37 Yu SY, Xu L. The interplay between host cellular and gut microbial metabolism in NAFLD development and prevention. J Appl Microbiol 2021;131:564-82. [PMID: 33411984 DOI: 10.1111/jam.14992] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, Yang QB, Hu H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2019;12:1756284819878046. [PMID: 31598135 DOI: 10.1177/1756284819878046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
39 Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr 2019;13:2917-22. [PMID: 31425956 DOI: 10.1016/j.dsx.2019.07.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
40 Cerdó T, Ruíz A, Suárez A, Campoy C. Probiotic, Prebiotic, and Brain Development. Nutrients 2017;9:E1247. [PMID: 29135961 DOI: 10.3390/nu9111247] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
41 S Lavekar A, V Raje D, Manohar T, A Lavekar A. Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. Euroasian J Hepatogastroenterol 2017;7:130-7. [PMID: 29201794 DOI: 10.5005/jp-journals-10018-1233] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
42 Zhang S, Fu J, Zhang Q, Liu L, Lu M, Meng G, Yao Z, Wu H, Xia Y, Bao X, Gu Y, Sun S, Wang X, Zhou M, Jia Q, Song K, Wu Y, Xiang H, Niu K. Association between habitual yogurt consumption and newly diagnosed non-alcoholic fatty liver disease.Eur J Clin Nutr. 2020;74:491-499. [PMID: 31477797 DOI: 10.1038/s41430-019-0497-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
43 Kosmalski M, Mokros Ł, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent Eur J Immunol 2018;43:231-9. [PMID: 30135638 DOI: 10.5114/ceji.2018.77395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
44 Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:15518-15531. [PMID: 25400436 DOI: 10.3748/wjg.v20.i42.15518] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
45 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients. 2014;6:5583-5599. [PMID: 25479248 DOI: 10.3390/nu6125583] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
46 Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev 2018;31:35-51. [PMID: 29037268 DOI: 10.1017/S095442241700018X] [Cited by in Crossref: 79] [Cited by in F6Publishing: 36] [Article Influence: 19.8] [Reference Citation Analysis]
47 Ghorbani Z, Hajizadeh M, Hekmatdoost A. Dietary supplementation in patients with alcoholic liver disease: a review on current evidence. Hepatobiliary & Pancreatic Diseases International 2016;15:348-60. [DOI: 10.1016/s1499-3872(16)60096-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
48 Velayati A, Kareem I, Sedaghat M, Sohrab G, Nikpayam O, Hedayati M, Abhari K, Hejazi E. Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. Arch Physiol Biochem 2021;:1-8. [PMID: 34077686 DOI: 10.1080/13813455.2021.1928225] [Reference Citation Analysis]
49 Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. Int J Mol Sci 2021;22:6485. [PMID: 34204274 DOI: 10.3390/ijms22126485] [Reference Citation Analysis]
50 Hormoznejad R, Mohammad Shahi M, Rahim F, Helli B, Alavinejad P, Sharhani A. Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. Int J Food Sci Nutr 2020;71:991-1000. [PMID: 32237922 DOI: 10.1080/09637486.2020.1746957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
51 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:3777-3785. [PMID: 25852263 DOI: 10.3748/wjg.v21.i13.3777] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 64] [Article Influence: 13.2] [Reference Citation Analysis]
52 Jalili R, Somi MH, Hosseinifard H, Salehnia F, Ghojazadeh M, Makhdami N, Shirmohammadi M. The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. Adv Pharm Bull. 2020;10:542-555. [PMID: 33072533 DOI: 10.34172/apb.2020.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, Poustchi H, Hedayati M, Aghajanpoor-Pasha M, Sadeghi A, Hekmatdoost A. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019;73:441-9. [PMID: 30610213 DOI: 10.1038/s41430-018-0382-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
54 Nawrot M, Peschard S, Lestavel S, Staels B. Intestine-liver crosstalk in Type 2 Diabetes and non-alcoholic fatty liver disease. Metabolism 2021;123:154844. [PMID: 34343577 DOI: 10.1016/j.metabol.2021.154844] [Reference Citation Analysis]
55 Abdou RM, Zhu L, Baker RD, Baker SS. Gut Microbiota of Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1268-1281. [PMID: 26898658 DOI: 10.1007/s10620-016-4045-1] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
56 Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Clément K. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open 2019;9:e017995. [PMID: 30928918 DOI: 10.1136/bmjopen-2017-017995] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 37.5] [Reference Citation Analysis]
57 Yari Z, Rahimlou M, Eslamparast T, Ebrahimi-Daryani N, Poustchi H, Hekmatdoost A. Flaxseed supplementation in non-alcoholic fatty liver disease: a pilot randomized, open labeled, controlled study. Int J Food Sci Nutr. 2016;67:461-469. [PMID: 26983396 DOI: 10.3109/09637486.2016.1161011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
58 Reddy AJ, George ES, Roberts SK, Tierney AC. Effect of dietary intervention, with or without co-interventions, on inflammatory markers in patients with nonalcoholic fatty liver disease: a systematic literature review. Nutr Rev 2019;77:765-86. [PMID: 31361003 DOI: 10.1093/nutrit/nuz029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
59 Mansour A, Mohajeri-Tehrani MR, Samadi M, Qorbani M, Merat S, Adibi H, Poustchi H, Hekmatdoost A. Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Nutr J 2021;20:35. [PMID: 33838673 DOI: 10.1186/s12937-021-00694-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837-843. [PMID: 25311610 DOI: 10.1016/j.nutres.2014.09.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 23.9] [Reference Citation Analysis]
61 Beserra BT, Fernandes R, do Rosario VA, Mocellin MC, Kuntz MG, Trindade EB. A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity. Clin Nutr 2015;34:845-58. [PMID: 25456608 DOI: 10.1016/j.clnu.2014.10.004] [Cited by in Crossref: 91] [Cited by in F6Publishing: 68] [Article Influence: 13.0] [Reference Citation Analysis]
62 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
63 Emamat H, Foroughi F, Eini-Zinab H, Taghizadeh M, Rismanchi M, Hekmatdoost A. The effects of onion consumption on treatment of metabolic, histologic, and inflammatory features of nonalcoholic fatty liver disease. J Diabetes Metab Disord. 2015;15:25. [PMID: 27453880 DOI: 10.1186/s40200-016-0248-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
64 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol 2020;17:687-701. [PMID: 32826966 DOI: 10.1038/s41575-020-0344-2] [Cited by in Crossref: 78] [Cited by in F6Publishing: 49] [Article Influence: 78.0] [Reference Citation Analysis]
66 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
67 Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;43:1109-23. [PMID: 27061197 DOI: 10.1111/apt.13620] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
68 Fernandes R, Beserra BT, Mocellin MC, Kuntz MG, da Rosa JS, de Miranda RC, Schreiber CS, Fröde TS, Nunes EA, Trindade EB. Effects of Prebiotic and Synbiotic Supplementation on Inflammatory Markers and Anthropometric Indices After Roux-en-Y Gastric Bypass: A Randomized, Triple-blind, Placebo-controlled Pilot Study. J Clin Gastroenterol 2016;50:208-17. [PMID: 25909598 DOI: 10.1097/MCG.0000000000000328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 5.2] [Reference Citation Analysis]
69 Fan H, Shen Y, Ren Y, Mou Q, Lin T, Zhu L, Ren T. Combined intake of blueberry juice and probiotics ameliorate mitochondrial dysfunction by activating SIRT1 in alcoholic fatty liver disease. Nutr Metab (Lond) 2021;18:50. [PMID: 33971886 DOI: 10.1186/s12986-021-00554-3] [Reference Citation Analysis]
70 Abhari K, Saadati S, Yari Z, Hosseini H, Hedayati M, Abhari S, Alavian SM, Hekmatdoost A. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN 2020;39:53-60. [PMID: 32859329 DOI: 10.1016/j.clnesp.2020.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
71 Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796-803. [PMID: 26234526 DOI: 10.1017/s0007114515002433] [Cited by in Crossref: 89] [Cited by in F6Publishing: 41] [Article Influence: 14.8] [Reference Citation Analysis]
72 Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923-930. [PMID: 26151226 DOI: 10.1016/j.clinbiochem.2015.06.023] [Cited by in Crossref: 128] [Cited by in F6Publishing: 120] [Article Influence: 21.3] [Reference Citation Analysis]
73 Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol. 2015;7:204-212. [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
74 Hernández-Ceballos W, Cordova-Gallardo J, Mendez-Sanchez N. Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. J Clin Transl Hepatol 2021;9:227-38. [PMID: 34007805 DOI: 10.14218/JCTH.2020.00131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
76 Hung CK, Bodenheimer HC Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:175-87. [PMID: 29128055 DOI: 10.1016/j.cld.2017.08.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
77 Yao F, Jia R, Huang H, Yu Y, Mei L, Bai L, Ding Y, Zheng P. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Arch Med Sci 2019;15:1336-44. [PMID: 31572482 DOI: 10.5114/aoms.2019.86611] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
78 Poeta M, Pierri L, Vajro P. Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. Children (Basel). 2017;4. [PMID: 28767077 DOI: 10.3390/children4080066] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
79 Aitbaev KA, Murkamilov IT, Fomin VV. [Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. Ter Arkh 2017;89:120-8. [PMID: 28914862 DOI: 10.17116/terarkh2017898120-128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Emamat H, Noori M, Foroughi F, Rismanchi M, Eini-Zinab H, Hekmatdoost A. An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. Middle East J Dig Dis. 2016;8:109-115. [PMID: 27252817 DOI: 10.15171/mejdd.2016.15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
81 Ferolla SM, Armiliato GN, Couto CA, Ferrari TC. Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. World J Hepatol. 2015;7:559-565. [PMID: 25848479 DOI: 10.4254/wjh.v7.i3.559] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
82 Ekhlasi G, Kolahdouz Mohammadi R, Agah S, Zarrati M, Hosseini AF, Arabshahi SS, Shidfar F. Do symbiotic and Vitamin E supplementation have favorite effects in nonalcoholic fatty liver disease? A randomized, double-blind, placebo-controlled trial. J Res Med Sci 2016;21:106. [PMID: 28250783 DOI: 10.4103/1735-1995.193178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
83 Nikkhah-bodaghi M, Ghanavati M, Hekmatdoost A. Polyphenol intakes and risk of impaired lipid profile, elevated hepatic enzymes and nonalcoholic fatty liver disease. NFS 2019;49:903-10. [DOI: 10.1108/nfs-12-2018-0338] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
84 Darabi Z, Darand M, Yari Z, Hedayati M, Faghihi A, Agah S, Hekmatdoost A. Inflammatory markers response to citrulline supplementation in patients with non-alcoholic fatty liver disease: a randomized, double blind, placebo-controlled, clinical trial. BMC Res Notes 2019;12:89. [PMID: 30767788 DOI: 10.1186/s13104-019-4130-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
85 Fernandes R, do Rosario VA, Mocellin MC, Kuntz MGF, Trindade EBSM. Effects of inulin-type fructans, galacto-oligosaccharides and related synbiotics on inflammatory markers in adult patients with overweight or obesity: A systematic review. Clin Nutr 2017;36:1197-206. [PMID: 27771020 DOI: 10.1016/j.clnu.2016.10.003] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
86 Gong Y, Lyu W, Shi X, Zou X, Lu L, Yang H, Xiao Y. A Serum Metabolic Profiling Analysis During the Formation of Fatty Liver in Landes Geese via GC-TOF/MS. Front Physiol 2020;11:581699. [PMID: 33381050 DOI: 10.3389/fphys.2020.581699] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
88 Darand M, Darabi Z, Yari Z, Hedayati M, Shahrbaf MA, Khoncheh A, Hosseini-Ahangar B, Alavian SM, Hekmatdoost A. The effects of black seed supplementation on cardiovascular risk factors in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled clinical trial. Phytother Res 2019;33:2369-77. [PMID: 31293021 DOI: 10.1002/ptr.6424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
89 Saltzman ET, Palacios T, Thomsen M, Vitetta L. Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. Front Microbiol 2018;9:61. [PMID: 29441049 DOI: 10.3389/fmicb.2018.00061] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 21.3] [Reference Citation Analysis]
90 Patel R, DuPont HL. New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis 2015;60 Suppl 2:S108-21. [PMID: 25922396 DOI: 10.1093/cid/civ177] [Cited by in Crossref: 122] [Cited by in F6Publishing: 98] [Article Influence: 24.4] [Reference Citation Analysis]
91 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
92 Nasri K, Jamilian M, Rahmani E, Bahmani F, Tajabadi-Ebrahimi M, Asemi Z. The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord 2018;18:21. [PMID: 29649996 DOI: 10.1186/s12902-018-0248-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
93 Tajiri K, Shimizu Y. Gut bacteria may control development of hepatocellular carcinoma. Hepatobiliary Surg Nutr 2017;6:417-9. [PMID: 29312980 DOI: 10.21037/hbsn.2017.07.05] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
94 Mahady SE, George J. Exercise and diet in the management of nonalcoholic fatty liver disease. Metabolism 2016;65:1172-82. [DOI: 10.1016/j.metabol.2015.10.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
95 Wang X, Yang J, Qiu X, Wen Q, Liu M, Zhou D, Chen Q. Probiotics, Pre-biotics and Synbiotics in the Treatment of Pre-diabetes: A Systematic Review of Randomized Controlled Trials. Front Public Health 2021;9:645035. [PMID: 33842424 DOI: 10.3389/fpubh.2021.645035] [Reference Citation Analysis]
96 Huang W, Kong D. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD. Biomedicine & Pharmacotherapy 2021;135:111235. [DOI: 10.1016/j.biopha.2021.111235] [Reference Citation Analysis]
97 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
98 Cassard AM, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr 2017;5. [PMID: 28840806 DOI: 10.1128/microbiolspec.BAD-0007-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
99 Noori M, Jafari B, Hekmatdoost A. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation. J Sci Food Agric 2017;97:2327-32. [PMID: 27717115 DOI: 10.1002/jsfa.8042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
100 Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;158:1597-1610. [PMID: 31987796 DOI: 10.1053/j.gastro.2020.01.031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 38.0] [Reference Citation Analysis]
101 Markowiak P, Śliżewska K. Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. Nutrients 2017;9:E1021. [PMID: 28914794 DOI: 10.3390/nu9091021] [Cited by in Crossref: 474] [Cited by in F6Publishing: 282] [Article Influence: 118.5] [Reference Citation Analysis]
102 Spahis S, Delvin E, Borys JM, Levy E. Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis. Antioxid Redox Signal. 2017;26:519-541. [PMID: 27452109 DOI: 10.1089/ars.2016.6776] [Cited by in Crossref: 173] [Cited by in F6Publishing: 152] [Article Influence: 34.6] [Reference Citation Analysis]
103 Alves CC, Waitzberg DL, de Andrade LS, Dos Santos Aguiar L, Reis MB, Guanabara CC, Júnior OA, Ribeiro DA, Sala P. Prebiotic and Synbiotic Modifications of Beta Oxidation and Lipogenic Gene Expression after Experimental Hypercholesterolemia in Rat Liver. Front Microbiol 2017;8:2010. [PMID: 29089934 DOI: 10.3389/fmicb.2017.02010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
104 Dietert RR, Dietert JM. The Microbiome and Sustainable Healthcare. Healthcare (Basel) 2015;3:100-29. [PMID: 27417751 DOI: 10.3390/healthcare3010100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
105 Gadallah SH, Eissa S, Ghanem HM, Ahmed EK, Hasanin AH, El Mahdy MM, Matboli M. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. Biomed Pharmacother 2021;140:111781. [PMID: 34090052 DOI: 10.1016/j.biopha.2021.111781] [Reference Citation Analysis]
106 Perdomo CM, Frühbeck G, Escalada J. Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients 2019;11:E677. [PMID: 30901929 DOI: 10.3390/nu11030677] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
107 Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, Wang Z, Brown JM, Hazen SL, Mandard S, Shiri-Sverdlov R, Kuipers F, Willems van Dijk K, Vervoort J, Stienstra R, Hooiveld GJEJ, Kersten S. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. J Lipid Res. 2017;58:1399-1416. [PMID: 28533304 DOI: 10.1194/jlr.m075713] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
108 Hernandez-Rodas MC, Valenzuela R, Videla LA. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2015;16:25168-98. [PMID: 26512643 DOI: 10.3390/ijms161025168] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 11.5] [Reference Citation Analysis]
109 Tan P, Eor J, Chun T, Kim S. Immune Modulation by Probiotics. In: Liong M, editor. Beneficial Microorganisms in Medical and Health Applications. Cham: Springer International Publishing; 2015. pp. 101-30. [DOI: 10.1007/978-3-319-23213-3_5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Kaliora AC, Kokkinos A, Diolintzi A, Stoupaki M, Gioxari A, Kanellos PT, Dedoussis GVZ, Vlachogiannakos J, Revenas C, Ladas SD, Karathanos VT. The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. Food Funct 2016;7:4533-44. [DOI: 10.1039/c6fo01040g] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
111 Karbaschian Z, Mokhtari Z, Pazouki A, Kabir A, Hedayati M, Moghadam SS, Mirmiran P, Hekmatdoost A. Probiotic Supplementation in Morbid Obese Patients Undergoing One Anastomosis Gastric Bypass-Mini Gastric Bypass (OAGB-MGB) Surgery: a Randomized, Double-Blind, Placebo-Controlled, Clinical Trial. OBES SURG 2018;28:2874-85. [DOI: 10.1007/s11695-018-3280-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
112 Maddur H, Neuschwander-Tetri BA. More evidence that probiotics may have a role in treating fatty liver disease. Am J Clin Nutr 2014;99:425-6. [PMID: 24500146 DOI: 10.3945/ajcn.113.082636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
113 Zou Y, Qi Z. Understanding the Role of Exercise in Nonalcoholic Fatty Liver Disease: ERS-Linked Molecular Pathways. Mediators Inflamm 2020;2020:6412916. [PMID: 32774148 DOI: 10.1155/2020/6412916] [Reference Citation Analysis]
114 Petrova P, Petrov K. Prebiotic–Probiotic Relationship: The Genetic Fundamentals of Polysaccharides Conversion by Bifidobacterium and Lactobacillus Genera. Food Bioconversion. Elsevier; 2017. pp. 237-78. [DOI: 10.1016/b978-0-12-811413-1.00007-3] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Silva-Sperb AS, Moraes HA, de Moura BC, Alves BC, Bruch-Bertani JP, Azevedo VZ, Dall'Alba V. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. Trials 2019;20:580. [PMID: 31601229 DOI: 10.1186/s13063-019-3679-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
116 Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis 2017;38:231-40. [DOI: 10.1093/carcin/bgx007] [Cited by in Crossref: 104] [Cited by in F6Publishing: 44] [Article Influence: 26.0] [Reference Citation Analysis]
117 Elvira-Torales LI, Periago MJ, González-Barrio R, Hidalgo N, Navarro-González I, Gómez-Gallego C, Masuero D, Soini E, Vrhovsek U, García-Alonso FJ. Spinach consumption ameliorates the gut microbiota and dislipaemia in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). Food Funct 2019;10:2148-60. [PMID: 30938723 DOI: 10.1039/c8fo01630e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 6.5] [Reference Citation Analysis]
118 Kim A, Krishnan A, Hamilton JP, Woreta TA. The Impact of Dietary Patterns and Nutrition in Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2021;50:217-41. [PMID: 33518166 DOI: 10.1016/j.gtc.2020.10.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. Eur J Nutr 2019;58:1735-45. [PMID: 29779170 DOI: 10.1007/s00394-018-1721-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
120 Rafiee P, Shivappa N, Hébert JR, Nasab SJ, Bahrami A, Hekmatdoost A, Rashidkhani B, Sadeghi A, Houshyari M, Hejazi E. Dietary Inflammatory Index and Odds of Colorectal Cancer and Colorectal Adenomatous Polyps in A Case-Control Study from Iran. Nutrients 2019;11:E1213. [PMID: 31142015 DOI: 10.3390/nu11061213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
121 Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management. World J Gastroenterol 2020;26:6514-28. [PMID: 33268944 DOI: 10.3748/wjg.v26.i42.6514] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
122 Pan X, Wen SW, Kaminga AC, Liu A. Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Sci Rep 2020;10:8848. [PMID: 32483129 DOI: 10.1038/s41598-020-65051-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
123 Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr 2018;57:2037-53. [PMID: 29119235 DOI: 10.1007/s00394-017-1568-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
124 Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A. Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. Int J Mol Sci 2016;17:E928. [PMID: 27304953 DOI: 10.3390/ijms17060928] [Cited by in Crossref: 126] [Cited by in F6Publishing: 102] [Article Influence: 25.2] [Reference Citation Analysis]
125 García-alonso FJ, González-barrio R, Martín-pozuelo G, Hidalgo N, Navarro-gonzález I, Masuero D, Soini E, Vrhovsek U, Periago MJ. A study of the prebiotic-like effects of tomato juice consumption in rats with diet-induced non-alcoholic fatty liver disease (NAFLD). Food Funct 2017;8:3542-52. [DOI: 10.1039/c7fo00393e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
126 Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial. BMC Gastroenterol. 2019;19:133. [PMID: 31345163 DOI: 10.1186/s12876-019-1055-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
127 Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab 2016;101:1445-54. [PMID: 26938201 DOI: 10.1210/jc.2015-4251] [Cited by in Crossref: 83] [Cited by in F6Publishing: 61] [Article Influence: 16.6] [Reference Citation Analysis]
128 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
129 Loman BR, Hernández-Saavedra D, An R, Rector RS. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Nutr Rev 2018;76:822-39. [PMID: 30113661 DOI: 10.1093/nutrit/nuy031] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
130 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol. 2015;7:2597-2602. [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
131 Raji Lahiji M, Zarrati M, Najafi S, Yazdani B, Cheshmazar E, Razmpoosh E, Janani L, Raji Lahiji M, Shidfar F. Effects of synbiotic supplementation on serum adiponectin and inflammation status of overweight and obese breast cancer survivors: a randomized, triple-blind, placebo-controlled trial. Support Care Cancer 2021;29:4147-57. [PMID: 33404812 DOI: 10.1007/s00520-020-05926-8] [Reference Citation Analysis]
132 Hegazy MA, Mogawer SM, Alnaggar ARLR, Ghoniem OA, Abdel Samie RM. Serum LPS and CD163 Biomarkers Confirming the Role of Gut Dysbiosis in Overweight Patients with NASH. Diabetes Metab Syndr Obes 2020;13:3861-72. [PMID: 33116732 DOI: 10.2147/DMSO.S249949] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
133 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
134 Hatton G, Alterio T, Nobili V, Mann JP. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future? Expert Review of Gastroenterology & Hepatology 2018;12:961-7. [DOI: 10.1080/17474124.2018.1512853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
135 Elhence A, Shalimar. Treatment of non-alcoholic fatty liver disease - Current perspectives. Indian J Gastroenterol 2020;39:22-31. [PMID: 32152902 DOI: 10.1007/s12664-020-01021-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
136 Machado D, Almeida D, Seabra CL, Andrade JC, Gomes AM, Freitas AC. Nanoprobiotics: When Technology Meets Gut Health. In: Thangadurai D, Sangeetha J, Prasad R, editors. Functional Bionanomaterials. Cham: Springer International Publishing; 2020. pp. 389-425. [DOI: 10.1007/978-3-030-41464-1_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
137 Jia W, Rajani C. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. Adv Exp Med Biol 2018;1061:95-110. [PMID: 29956209 DOI: 10.1007/978-981-10-8684-7_8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
138 Suk KT, Kim DJ. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2019;13:193-204. [PMID: 30791767 DOI: 10.1080/17474124.2019.1569513] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
139 Agosti P, Sabbà C, Mazzocca A. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:607-17. [DOI: 10.1016/j.bbadis.2017.11.026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
140 Roychowdhury S, Selvakumar PC, Cresci GAM. The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Med Sci (Basel) 2018;6:E47. [PMID: 29874807 DOI: 10.3390/medsci6020047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
141 Emamat H, Foroughi F, Eini-Zinab H, Hekmatdoost A. The Effects of Onion Consumption on Prevention of Nonalcoholic Fatty Liver Disease. Indian J Clin Biochem 2018;33:75-80. [PMID: 29371773 DOI: 10.1007/s12291-017-0636-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
142 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
143 Karimi E, Moini A, Yaseri M, Shirzad N, Sepidarkish M, Hossein-boroujerdi M, Hosseinzadeh-attar MJ. Effects of synbiotic supplementation on metabolic parameters and apelin in women with polycystic ovary syndrome: a randomised double-blind placebo-controlled trial. Br J Nutr 2018;119:398-406. [DOI: 10.1017/s0007114517003920] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 5.7] [Reference Citation Analysis]
144 Reid G. The growth potential for dairy probiotics. International Dairy Journal 2015;49:16-22. [DOI: 10.1016/j.idairyj.2015.04.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
145 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
146 Mansour A, Hekmatdoost A, Mirmiran P. What are the main areas of focus to prevent or treat non‐alcoholic fatty liver disease? J Dig Dis 2019;20:271-7. [DOI: 10.1111/1751-2980.12751] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Picardo SL, Coburn B, Hansen AR. The microbiome and cancer for clinicians. Crit Rev Oncol Hematol. 2019;141:1-12. [PMID: 31202124 DOI: 10.1016/j.critrevonc.2019.06.004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]
148 Chen HT, Huang HL, Li YQ, Xu HM, Zhou YJ. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World J Gastroenterol 2020;26:1901-11. [PMID: 32390701 DOI: 10.3748/wjg.v26.i16.1901] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
149 Duarte SMB, Stefano JT, Oliveira CP. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 2019;18:416-21. [PMID: 31036494 DOI: 10.1016/j.aohep.2019.04.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
150 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
151 Ahn SB, Jun DW, Kang BK, Lim JH, Lim S, Chung MJ. Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease. Sci Rep. 2019;9:5688. [PMID: 30952918 DOI: 10.1038/s41598-019-42059-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 17.5] [Reference Citation Analysis]
152 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
153 Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019;110:139-49. [PMID: 31124558 DOI: 10.1093/ajcn/nqz042] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
154 Miloh T. Probiotics in Pediatric Liver Disease. J Clin Gastroenterol 2015;49 Suppl 1:S33-6. [PMID: 26447962 DOI: 10.1097/MCG.0000000000000365] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
155 Darand M, Darabi Z, Yari Z, Saadati S, Hedayati M, Khoncheh A, Hosseini-ahangar B, Alavian SM, Hekmatdoost A. Nigella sativa and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Results from a randomized, double-blind, placebo-controlled, clinical trial. Complementary Therapies in Medicine 2019;44:204-9. [DOI: 10.1016/j.ctim.2019.04.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
156 Cho MS, Kim SY, Suk KT, Kim BY. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. J Microbiol. 2018;56:855-867. [PMID: 30377993 DOI: 10.1007/s12275-018-8346-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
157 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:7495-7504. [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
158 Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Critical Reviews in Food Science and Nutrition 2019;59:2494-505. [DOI: 10.1080/10408398.2018.1458021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]